Literature DB >> 10837091

Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis.

P A Isotalo1, J G Donnelly.   

Abstract

BACKGROUND: The objectives of this study are to examine the prevalence of combined methylenetetrahydrofolate reductase (MTHFR) 677C-->T and 1298A-->C mutations in patients with venous thrombosis (VT) and healthy volunteers and to determine if these mutations are in Hardy-Weinberg equilibrium. METHODS AND
RESULTS: Sixty-five patients with VT and 64 healthy volunteers were assessed for MTHFR 677T and 1298C alleles using polymerase chain reaction and restriction fragment length polymorphism. Observed MTHFR genotype frequencies were compared with expected genotype combinations, and their odds ratios were determined. MTHFR allele frequency did not differ between VT and control groups; however, differences were observed for MTHFR genotype distribution. MTHFR 677T and 1298C alleles occurred in cis in our population, and therefore mutation crossover has occurred. There was deviation from the Hardy-Weinberg equilibrium for combined MTHFR genotypes, although this may at least partly be attributable to linkage disequilibrium. MTHFR 677CT/1298CC and 677TT/1298CC genotypes (P<.05) were not observed in either group.
CONCLUSIONS: The absence of MTHFR 677CT/1298CC and 677TT/1298CC genotypes in both groups suggests that certain MTHFR genotypes may carry a selective advantage. Our discovery of a substantial number of MTHFR mutations in cis configuration suggests that any MTHFR allele linkage disequilibrium present is incomplete.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837091     DOI: 10.1007/bf03262024

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  30 in total

Review 1.  Hyperhomocyst(e)inemia and atherothrombosis.

Authors:  G N Welch; G Upchurch; J Loscalzo
Journal:  Ann N Y Acad Sci       Date:  1997-04-15       Impact factor: 5.691

Review 2.  Oral contraceptives and thrombotic disease: risk of venous thromboembolism.

Authors:  F M Helmerhorst; K W Bloemenkamp; F R Rosendaal; J P Vandenbroucke
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

3.  High frequency (71%) of cystathionine beta-synthase mutation G307S in Irish homocystinuria patients.

Authors:  P M Gallagher; P Ward; S Tan; E Naughten; J P Kraus; G C Sellar; D J McConnell; I Graham; A S Whitehead
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

Review 4.  Clinical chemistry and molecular biology of homocysteine metabolism: an update.

Authors:  S E Miner; J Evrovski; D E Cole
Journal:  Clin Biochem       Date:  1997-04       Impact factor: 3.281

5.  Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis.

Authors:  L A Kluijtmans; M den Heijer; P H Reitsma; S G Heil; H J Blom; F R Rosendaal
Journal:  Thromb Haemost       Date:  1998-02       Impact factor: 5.249

6.  Risk of Venous Thrombosis in Carriers of a Common Mutation in the Homocysteine Regulatory Enzyme Methylenetetrahydrofolate Reductase.

Authors: 
Journal:  Mol Diagn       Date:  1997-03

7.  Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss.

Authors:  M G Wouters; G H Boers; H J Blom; F J Trijbels; C M Thomas; G F Borm; R P Steegers-Theunissen; T K Eskes
Journal:  Fertil Steril       Date:  1993-11       Impact factor: 7.329

8.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

9.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.

Authors:  P F Jacques; A G Bostom; R R Williams; R C Ellison; J H Eckfeldt; I H Rosenberg; J Selhub; R Rozen
Journal:  Circulation       Date:  1996-01-01       Impact factor: 29.690

10.  Homocysteine metabolism in pregnancies complicated by neural-tube defects.

Authors:  J L Mills; J M McPartlin; P N Kirke; Y J Lee; M R Conley; D G Weir; J M Scott
Journal:  Lancet       Date:  1995-01-21       Impact factor: 79.321

View more
  10 in total

1.  A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis.

Authors:  Wassim Y Almawi; Hala Tamim; Raghid Kreidy; Georgina Timson; Elias Rahal; Malak Nabulsi; Ramzi R Finan; Noha Irani-Hakime
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

2.  Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations.

Authors:  P A Isotalo; G A Wells; J G Donnelly
Journal:  Am J Hum Genet       Date:  2000-08-24       Impact factor: 11.025

3.  Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.

Authors:  Benedetto Simone; Valerio De Stefano; Emanuele Leoncini; Jeppe Zacho; Ida Martinelli; Joseph Emmerich; Elena Rossi; Aaron R Folsom; Wassim Y Almawi; Pierre Y Scarabin; Martin den Heijer; Mary Cushman; Silvana Penco; Amparo Vaya; Pantep Angchaisuksiri; Gulfer Okumus; Donato Gemmati; Simona Cima; Nejat Akar; Kivilcim I Oguzulgen; Véronique Ducros; Christoph Lichy; Consuelo Fernandez-Miranda; Andrzej Szczeklik; José A Nieto; Jose Domingo Torres; Véronique Le Cam-Duchez; Petar Ivanov; Carlos Cantu-Brito; Veronika M Shmeleva; Mojka Stegnar; Dotun Ogunyemi; Suhair S Eid; Nicola Nicolotti; Emma De Feo; Walter Ricciardi; Stefania Boccia
Journal:  Eur J Epidemiol       Date:  2013-07-31       Impact factor: 8.082

4.  Polymorphisms in the MTHFR gene influence embryo viability and the incidence of aneuploidy.

Authors:  María Enciso; Jonás Sarasa; Leoni Xanthopoulou; Sara Bristow; Megan Bowles; Elpida Fragouli; Joy Delhanty; Dagan Wells
Journal:  Hum Genet       Date:  2016-04-11       Impact factor: 4.132

5.  Impact of thrombophilic genetic factors on pulmonary embolism: early onset and recurrent incidences.

Authors:  Petar Ivanov; Regina Komsa-Penkova; Katia Kovacheva; Yavor Ivanov; Angelina Stoyanova; Ivan Ivanov; Plamen Pavlov; Pavlina Glogovska; Venzislav Nojarov
Journal:  Lung       Date:  2007-12-21       Impact factor: 2.584

6.  Frequency and association of 1691 (G>A) FVL, 20210 (G>A) PT and 677 (C>T) MTHFR with deep vein thrombosis in the population of Bosnia and Herzegovina.

Authors:  A Jusić-Karić; R Terzić; Z Jerkić; A Avdić; M Pođanin
Journal:  Balkan J Med Genet       Date:  2016-08-02       Impact factor: 0.519

7.  Meta-analysis of the relationship between methylenetetrahydrofolate reductase C677T and A1298C polymorphism and venous thromboembolism in the Caucasian and Asian.

Authors:  Miao Gao; Na Feng; Meixia Zhang; Xinyu Ti; Xiuping Zuo
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

Review 8.  Genetics and Epigenetics of One-Carbon Metabolism Pathway in Autism Spectrum Disorder: A Sex-Specific Brain Epigenome?

Authors:  Veronica Tisato; Juliana A Silva; Giovanna Longo; Ines Gallo; Ajay V Singh; Daniela Milani; Donato Gemmati
Journal:  Genes (Basel)       Date:  2021-05-20       Impact factor: 4.096

9.  Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms resulting in suboptimal oocyte maturation: a discussion of folate status, neural tube defects, schizophrenia, and vasculopathy.

Authors:  Piet Hein Jongbloet; André Lm Verbeek; Martin den Heijer; Nel Roeleveld
Journal:  J Exp Clin Assist Reprod       Date:  2008-07-10

10.  The methylenetetrahydrofolate reductase 677T-1298C haplotype is a risk factor for acute lymphoblastic leukemia in children.

Authors:  Ewelina Maria Kałużna; Ewa Strauss; Bogna Świątek-Kościelna; Olga Zając-Spychała; Ewelina Gowin; Jerzy S Nowak; Jolanta Rembowska; Danuta Januszkiewicz-Lewandowska
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.